Lana Pine is the editor of HCPLive Rheumatology. She is an experienced editor and technical writer with a demonstrated history of working in the banking and publishing industries. In her free time, she enjoys cooking, yoga, listening to podcasts, and drawing. She can be reached via email at LPine@mjhlifesciences.com.
Philip Mease, MD: Guselkumab Achieves Long-term Improvements in Psoriatic Arthritis Symptoms
December 1st 2021Philip Mease, MD, explains the recent Phase 3 data from the DISCOVER-1 and DISCOVER-2 clinical trials which demonstrated guselkumab inhibited radiographic progression, and improved symptoms and pain in patients with active psoriatic arthritis (PsA).
Read More
Benjamin Terrier, MD, PhD: Rituximab for Eosinophilic Granulomatosis with Polyangiitis
November 30th 2021Benjamin Terrier, MD, PhD, discusses his study and ACR presentation, “Rituximab versus Conventional Therapeutic Strategy for Remission Induction in Eosinophilic Granulomatosis with Polyangiitis: A Double-blind, Randomized, Controlled Trial.”
Read More
Cynthia Aranow, MD: Efficacy of Belimumab for Patients With Systemic Lupus Erythematosus
November 8th 2021"The primary efficacy endpoint was the proportion of patients with disease control without other immunosuppressants and prednisone-equivalent dose of ≤5 mg/day at week 52," Aranow stated.
Read More
Kazuki Yoshida, ScD: Gout Treatment Strategies Regarding Cardiovascular Outcomes
November 5th 2021Kazuki Yoshida, MD, MPH, ScD, discusses his ACR presentation entitled, “Comparative Safety of Gout "Treat-to-target" and "Usual Care" Treatment Strategies on Cardiovascular Outcomes Using Observational Data: Causal Inference Approach.”
Read More
Vibeke Strand, MD: Assessing Correlations of Patient-Reported Outcomes in Rheumatoid Arthritis
November 4th 2021Vibeke Strand, MD, explores her ACR presentation, “Assessing the Relationship of Patient Global Assessment of Disease Activity and Health Related Quality of Life by SF-36 with Other Patient-Reported Outcomes in Rheumatoid Arthritis: Post Hoc Analyses of Data from Phase 3 Trials of Baricitinib.”
Read More